CA
NZ
UK
AU
IND
US
Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage biotech, has expanded its pipeline through a licensing agreement with PharmAla Biotech, adding a new MDMA-based therapeutic candidate alongside its existing Parkinson's disease program.
Liminatus Pharma, Inc. (NASDAQ:LIMN), a clinical-stage biotech, is working through a pivotal stretch involving a proposed merger with oncology cell-therapy company InnocsAI and steps to maintain its Nasdaq listing.
Cytek Biosciences, Inc. (NASDAQ:CTKB) is weighing its next legal steps after a Delaware jury ruled that several of its spectral flow cytometry products infringe a patent held by Beckman Coulter, a Danaher subsidiary, and ordered the company to pay $56 million in damages.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), the synthetic-biology company, continues building out its automated laboratory infrastructure as it works to transition from legacy program revenue toward a platform-based business model.
electroCore, Inc. (NASDAQ:ECOR), the bioelectronic medicine company behind the gammaCore vagus nerve stimulator and the consumer-facing Truvaga device, raised its full-year revenue guidance following strong second-quarter results.
Apnimed, Inc. (NASDAQ:APMD), the Cambridge, Massachusetts drug developer, is advancing its lead sleep-apnea candidate through the FDA review process following a recentNasdaqdebut that raised roughly $220.8 million.
Tempus AI, Inc. (NASDAQ:TEM), the precision-medicine and AI diagnostics company, reported its first GAAP-profitable quarter alongside continued double-digit revenue growth, while advancing a pendingAcquisitionthat would expand its oncology monitoring capabilities.
Serina Therapeutics, Inc. (NYSE American:SER), a clinical-stage biotech, has completed a key enrollment milestone in its Phase 1b trial evaluating SER-252 for advanced Parkinson's disease.
Profusa, Inc. (NASDAQ:PFSA), a biosensor and diagnostics company, is working toward closing a transformativeAcquisitionwhile managing a distressedBalance Sheetand its Nasdaq listing requirements.
The company's request for a hearing before a Nasdaq Hearings Panel is a strategic move in its appeal process, offering an opportunity to contest the decision and seek to maintain its listing on Nasdaq. The timing of this request is critical as it occurs …
Please wait processing your request...